



# Ravenscroft Investment Fund Offshore Global Blue Chip Fund

**INVESTMENT MANAGERS: RAVENSCROFT INVESTMENT MANAGEMENT LIMITED**

## THEME WEIGHTINGS



**32% Healthcare**  
- Pharmaceuticals  
- Medical Devices

**32% Global Brands**  
- Consumer Staples  
- Consumer Discretionary

**28% Technology & Innovation**  
- Information Technology  
- Engineering & Industrials

**8% Cash & Equivalents**

## PERFORMANCE CHART



## FUND AIMS AND OBJECTIVES

The Global Blue Chip Fund's main objective is to generate long-term capital growth from a focused portfolio of large global businesses, which are listed on recognised stock exchanges in developed countries. It is actively managed and not constrained by a benchmark.

Ravenscroft Global Blue Chip is a sub-fund of the Ravenscroft Investment Fund Offshore; an open-ended, multi-class Unit Trust authorised as a Class B Scheme by the Guernsey Financial Services Commission.

## FUND SIZE: £145.7 M

Past performance is not a reliable indicator of future results.

## FUND MANAGER COMMENTARY

Your fund returned 2.6% during December and by comparison, the MSCI World Index was up 2.7%. The relative outperformance this month was attributable to asset allocation. As an investor, you will be aware that we have overweight positions relative to the market in Consumer Staples and Healthcare and both sectors performed well this month. From a stock selection perspective, our picks within these sectors (grossed-up) marginally underperformed their respective sector returns but still outperformed the overall market return. Stock picks in Consumer Discretionary and Communication Services outperformed their respective sectors, but marginally underperformed the market return.

It was a tricky month for Technology as investors remained risk averse and cautious around the Fed's intentions on asset tapering and interest rates, our underweight position served us well. So why the damp end to 2021? We suspect because investors have had a difficult year to navigate and with no clear direction on monetary policy, many

investors will have pulled the plug and taken a well earned rest. On a year-to-date basis the fund has returned 15.5% despite all the gyrations around inflation and interest rate expectations.

This month's top contributor was Edward Lifesciences returning 19.4% and contributing 0.4% to the overall performance. The largest detractor was Oracle falling 4.6% and impacting returns by 0.2%. News around its intention to acquire Cerner for \$28.3bn obviously rattled investors but we think the acquisition could pave a gateway for Oracle to significantly increase exposure to one of its strategic verticals: Healthcare. Cerner, one of the leaders in electronic healthcare records, would become a dedicated business unit within Oracle. While the market continues to process the implications of the deal, we think there are multiple routes towards adding value. First, Oracle can rapidly accelerate Cerner's cloud transition by moving its systems onto Oracle's best-in-class cloud infrastructure, made easier by the fact that Cerner already operates

on Oracle's database - this will serve to increase both revenues and margins. Second, by following the model of 2016's Netsuite acquisition, Oracle will have a good shot at significantly expanding Cerner's business outside the US. Third, by combining the leaders in database and healthcare record technologies, we believe this deal could ultimately enable the use healthcare data in increasingly innovative ways and valuable ways.

Towards the end of the month, we introduced Netflix, the global streaming giant to the strategy. We have been long admirers of the Company's ability to defy the odds and with the investment case significantly de-risked from a financial perspective, we used the weakness in the NASDAQ to initiate a small position. We will write more about our latest acquisition in this quarter's Stock in Focus.

The purchase was funded by the sale of half of the Fund's position in 3M where we feel the investment case is weaker than Netflix's at this point in time.

Financial Promotion - The value of the Fund may go down as well as up - you may get back less than you invested.

### 3 YEAR PERFORMANCE BREAKDOWN

	JAN	FEB	MAR	APR	MAY	JUNE	JULY	AUG	SEPT	OCT	NOV	DEC	YTD
2019	0.67%	3.02%	4.61%	2.44%	-0.18%	5.51%	4.09%	0.19%	-0.36%	-3.38%	2.55%	0.11%	20.64%
2020	0.43%	-5.04%	-3.44%	6.53%	5.27%	0.28%	-2.87%	3.12%	1.01%	-4.42%	7.34%	1.82%	9.46%
2021	-1.61%	-0.81%	4.93%	3.89%	1.16%	3.57%	2.53%	1.81%	-4.42%	2.79%	-1.49%	2.61%	15.52%

Past performance is not a guide to future performance and may not be repeated. Source: Ravenscroft Investment Management Limited, collated 05/01/2022

### PERFORMANCE ANALYSIS (Inception date: 1 July 2014)

1 Year	3 Year	5 Year	Inception	Annual Compound Growth Rate
15.5%	52.6%	59.0%	121.0%	11.2%

All figures are based on the Fund's 'O' Dist class, inclusive of fees and assuming all dividends are reinvested.

### BLUE CHIP PORTFOLIO

FUND	WEIGHTING
<b>Global Brands</b>	
Adidas	1.9%
BMW	3.9%
Colgate-Palmolive	2.5%
Diageo	3.6%
Henkel	3.6%
L'Oreal	2.8%
LVMH	3.0%
Nike	2.0%
PepsiCo	2.5%
Richemont	0.1%
Unilever	3.1%
Walt Disney	3.5%
	<b>32.5%</b>
<b>Technology &amp; Innovation</b>	
3M	2.0%
Alphabet	2.9%
Dropbox	1.9%
eBay	1.7%
Honeywell	3.7%
Microsoft	2.9%
Netflix	2.0%
Oracle	4.1%
Relx	3.1%
Visa	3.2%
	<b>27.5%</b>
<b>Healthcare</b>	
Alnylam Pharmaceuticals	1.8%
Edward Lifesciences	2.5%
GlaxoSmithKline	4.2%
Illumina	2.2%
Johnson & Johnson	4.0%
Medtronic	3.7%
Regeneron Pharmaceuticals	2.9%
Roche	4.6%
Sanofi	4.1%
Waters	2.5%
	<b>32.5%</b>
<b>Cash &amp; Equivalents</b>	
Cash	7.1%
JPMorgan Sterling Liquidity	0.4%

### DIVIDEND HISTORY

Historic Yield 1.1%

#### Semi-Annual Dividend Announcement

Ex Date:	1st April 2021
Rate per O unit:	DIST: £0.92 ACC: £1.02
Rate per I unit:	DIST: £0.90 ACC: £1.00
Ex Date:	1st October 2021
Rate per O unit:	DIST: £1.26 ACC: £1.40
Rate per I unit:	DIST: £1.23 ACC: £1.38

Dividends are paid a calendar month after each half year. Please note that income levels are not guaranteed and can fluctuate.

### KEY POINTS

#### Dealing Frequency:

Daily (cut-off 5pm GMT one Business Day prior to Dealing Day)

#### Settlement Period: T+4

#### Annual Management Fee: 'O' Class - 0.75% (Retail)

'I' Class - 1.0% (Introducer/Advisor)

'S' Class 0.50% (Institutional)

#### Minimum Investment: 'O' and 'I': £5,000.00 'S' Class: £10,000,000.00

Sedol / ISIN: 'O' Class ACC: BN707P7 / GGO0BN707P73

DIST: BN707Q8 / GGO0BN707Q80

'I' Class ACC: BN707M4 / GGO0BN707M43

DIST: BN707N5 / GGO0BN707N59

'S' Class ACC: BMH70Q3 / GGO0BMH70Q35

DIST: BMH70R4 / GGO0BMH70R42

#### Trustees: BNP Paribas Securities Services S.C.A. Guernsey Branch

A copy of the Trust Instrument and Scheme Particulars can be obtained by contacting the Administrator:

Sanne Fund Services (Guernsey) Limited (Previously known as Praxis Fund Services Limited) T: +44 1481 737600 E: Ravenscroft@PraxisFM.com

For further information from the Manager, please use the below details:

**20 New Street, St Peter Port, Guernsey, GY1 4JG**

**t +44 (0)1481 729100 w ravenscroftgroup.com**

Ravenscroft is a trading name of Ravenscroft Investment Management Limited ("RIML"), which is licensed and regulated by the Guernsey Financial Services Commission to conduct investment business. For all Ravenscroft connected entities, please refer to [www.ravenscroftgroup.com/disclaimer](http://www.ravenscroftgroup.com/disclaimer). All calls will be recorded and monitored for training and security purposes. This is not an offer or solicitation with respect to the purchase or sale of any security. This fact sheet is intended only to facilitate your discussions with Ravenscroft as to the opportunities available to our clients. The given material is subject to change and, although based upon information which we consider reliable, it is not guaranteed as to accuracy or completeness and it should not be relied upon as such. The material is not intended to be used as a general guide to investing, or as a source of any specific investment recommendations, and makes no implied or express recommendations concerning the manner in which any client's account should or would be handled, as appropriate investment strategies depend upon client's investment objectives. This material does not constitute an offer or solicitation to any person in any jurisdiction in which such offer or solicitation is not authorised or to any person to whom it would be unlawful to make such offer or solicitation. It is the responsibility of any person or persons in possession of this material to inform themselves of and to observe all applicable laws and regulations of any relevant jurisdiction. Prospective investors should inform themselves and take appropriate advice as to any applicable legal requirements and any applicable taxation and exchange control regulations in the countries of their citizenship, residence or domicile which might be relevant to the subscription, purchase, holding, exchange, redemption or disposal of any investments. Ravenscroft does not provide tax advice to its clients and all investors are strongly advised to consult with their tax advisors regarding any potential investment. Opinions expressed are our current opinions as of the date appearing on this material only. Any historical price(s) or value(s) are also only as of the date indicated. While we endeavour to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. Certain transactions, including those involving futures, options and high yield securities and investments in emerging markets may give rise to substantial risk and may not be suitable for all investors. Foreign currency denominated investments are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of, or income derived from, the investment; such investments are also subject to the possible imposition of exchange control regulations or other laws or restrictions applicable to such investments. Investments referred to in this material are not necessarily available in all jurisdictions, may be illiquid and may not be suitable for all investors. Investors should consider whether an investment is suitable for their particular circumstances and seek advice from Ravenscroft. The price and value of the investments referred to in this material and the income from them may go down as well as up and investors may realise losses on any investments. Past performance is not a guide to future performance. Future returns are not guaranteed and a loss of principal may occur.